Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01542060
NCT01542060CompletedNot Applicable

A Clinical Experience Programme to Collect Data on the Safety and Efficacy of NovoMix® 30 in the Treatment of Patients With Type 2 Diabetes in Jordan

Novo Nordisk A/S0 sites298 target enrollmentStarted: January 2004Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
298
Primary Endpoint
HbA1c (glycosylated haemoglobin)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects from hospitals or clinics, diagnosed with type 2 diabetes mellitus

Exclusion Criteria

  • Not provided

Arms & Interventions

BIAsp 30 users

Intervention: biphasic insulin aspart 30 (Drug)

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

  • Incidence of adverse events
  • Incidence of hypoglycaemic episodes
  • FBG (Fasting Blood Glucose)
  • Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)

Investigators

Sponsor Class
Industry

Similar Trials

Completed
Not Applicable
Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™Delivery SystemsDiabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
NCT00675220Novo Nordisk A/S373
Completed
Not Applicable
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 DiabetesDelivery SystemsDiabetesDiabetes Mellitus, Type 2
NCT00715663Novo Nordisk A/S1,584
Completed
Not Applicable
Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic AgentsDiabetesDiabetes Mellitus, Type 2
NCT00715780Novo Nordisk A/S1,667
Withdrawn
Not Applicable
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney DiseaseDiabetesChronic Kidney DiseaseDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
NCT00849316Novo Nordisk A/S
Completed
Not Applicable
An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East CountriesDiabetesDiabetes Mellitus, Type 2
NCT00842192Novo Nordisk A/S2,155